# BARIcitinib Cognitive Emotional and Neural signaTuRE

> **NCT05238896** · PHASE4 · TERMINATED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 5 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Baricitinib Oral Tablet [Olumiant]
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05238896
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-27
- **Primary completion:** 2023-02-23
- **Final completion:** 2023-03-31
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Difficulties of inclusion in the study following expiry of the experimental treatment. The time required to supply the study treatment is too long to obtain conclusive results at the end of the study.
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05238896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05238896, "BARIcitinib Cognitive Emotional and Neural signaTuRE". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05238896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*